ArticleJournal of psychoactive drugs
Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study.
Article in Journal of psychoactive drugs. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04521920 (Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Providing Comprehensive Harm Reduction Via Telemedicine for PWID Using Syringe Services Programs: a Feasibility Study
Who cites it
20 citing papers in PubMed, 33 citations in OpenAlex.
- Providing medication for opioid use disorder and HIV pre-exposure prophylaxis at syringe services programs via telemedicine: a pilot study.Harm reduction journal · 2024Trial
- An Individualized, Interdisciplinary Approach to the Perioperative Care of Patients on Buprenorphine.Current pain and headache reports · 2026Review
- Supporting Family Recovery: How Local Behavioral Health Boards Coordinate Child Welfare and Behavioral Health Systems for Parents and Caregivers With Substance Use Disorder.American journal of public health · 2026Article
- "They should be like penicillin": barriers to the integration of medications for opioid use disorder in specialty treatment programs.Addiction science & clinical practice · 2025Article
- An Approach to Enhancing Medication Treatment for Opioid Use Disorder in the HEALing Communities Study.Psychiatric services (Washington, D.C.) · 2024Article
- Medications for opioid use disorder in rural primary care practices: Patient and provider experiences.Journal of substance use and addiction treatment · 2023Article
- Building medication for opioid use disorder prescriber capacity during the opioid epidemic: Prescriber recruitment trends and methods.Journal of substance use and addiction treatment · 2023Article
- Trajectories of non-prescribed buprenorphine and other opioid use: A multi-trajectory latent class growth analysis.Journal of substance use and addiction treatment · 2023Article
- Association of Project ECHO Training With Buprenorphine Prescribing by Primary Care Clinicians in Minnesota for Treating Opioid Use Disorder.JAMA health forum · 2022Article
- Survey of Barriers and Facilitators to Prescribing Buprenorphine and Clinician Perceptions on the Drug Addiction Treatment Act of 2000 Waiver.JAMA network open · 2022Article
- Trends in and Characteristics of Buprenorphine Misuse Among Adults in the US.JAMA network open · 2021Article
- The Relationship Between Hepatitis C Virus Rates and Office-Based Buprenorphine Access in Ohio.Open forum infectious diseases · 2021Article
- Emergency physician perspectives on initiating buprenorphine/naloxone in the emergency department: A qualitative study.Journal of the American College of Emergency Physicians open · 2021Article
- Barriers and Facilitators to the Use of Medications for Opioid Use Disorder: a Rapid Review.Journal of general internal medicine · 2020Review
- On my own terms: Motivations for self-treating opioid-use disorder with non-prescribed buprenorphine.Drug and alcohol dependence · 2020Article
- Opiate and Cerebral Atrophy.Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine · 2020Article
- Characterization of diverted buprenorphine use among adults entering corrections-based drug treatment in Kentucky.Drug and alcohol dependence · 2020Article
- Thematic Analysis of Reddit Content About Buprenorphine-naloxone Using Manual Annotation and Natural Language Processing Techniques.Journal of addiction medicineArticle
- Buprenorphine Waiver Attitudes Among Primary Care Providers.Journal of primary care & community healthArticle
- Bridging the Macro-micro Divide: A Qualitative Meta-synthesis on the Perspectives and Experiences of Health Care Providers on the Extramedical Use and Diversion of Buprenorphine.Journal of addiction medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
Buprenorphine partial opioid agonist pharmacotherapy, a key treatment for opioid use disorders (OUDs), is underutilized in the United States. Qualitative interviews, conducted in 2012/2013 and repeated in 2015, identified systemic barriers to providing buprenorphine treatment in Ohio. A representative sample of Ohio's Alcohol, Drug Abuse and Mental Health Services (ADAMHS) county boards (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.